Abstract
Neurodegenerative disorders, e.g., Alzheimer’s disease (AD) and Parkinson’s disease (PD) are characterized by the progressive loss of neurons and subsequent cognitive decline. They are mainly found in older populations. Due to increasing life expectancies, the toll inflicted upon society by these disorders continues to become heavier and more prominent. Despite extensive research, however, the exact etiology of these disorders is still unknown, though the pathophysiological mechanisms have been attributed to oxidative, inflammatory and apoptotic injury in the brain. Moreover, there is currently no promising therapeutic agent against these neurodegenerative changes. Catalpol, an iridoid glucoside contained richly in the roots of the small flowering plant species Rehmannia glutinosa Libosch, has been shown to have antioxidation, anti-inflammation, anti-apoptosis and other neuroprotective properties and plays a role in neuroprotection against hypoxic/ischemic injury, AD and PD in both in vivo and in vitro models. It may therefore represent a potential therapeutical agent for the treatment of hypoxic/ischemic injury and neurodegenerative diseases. Based on our studies and those of others in the literature, here we comprehensively review the role of Catalpol in neuroprotection against pathological conditions, especially in neurodegenerative states and the potential mechanisms involved.
Keywords: Catalpol, neurodegenerative disease, neuroprotection, oxidant stress, inflammation, mitochondria, NF-κB, neurotrophins.
Current Medicinal Chemistry
Title:Catalpol: A Potential Therapeutic for Neurodegenerative Diseases
Volume: 22 Issue: 10
Author(s): B. Jiang, R.F. Shen, J. Bi, X.S. Tian, T Hinchliffe and Y. Xia
Affiliation:
Keywords: Catalpol, neurodegenerative disease, neuroprotection, oxidant stress, inflammation, mitochondria, NF-κB, neurotrophins.
Abstract: Neurodegenerative disorders, e.g., Alzheimer’s disease (AD) and Parkinson’s disease (PD) are characterized by the progressive loss of neurons and subsequent cognitive decline. They are mainly found in older populations. Due to increasing life expectancies, the toll inflicted upon society by these disorders continues to become heavier and more prominent. Despite extensive research, however, the exact etiology of these disorders is still unknown, though the pathophysiological mechanisms have been attributed to oxidative, inflammatory and apoptotic injury in the brain. Moreover, there is currently no promising therapeutic agent against these neurodegenerative changes. Catalpol, an iridoid glucoside contained richly in the roots of the small flowering plant species Rehmannia glutinosa Libosch, has been shown to have antioxidation, anti-inflammation, anti-apoptosis and other neuroprotective properties and plays a role in neuroprotection against hypoxic/ischemic injury, AD and PD in both in vivo and in vitro models. It may therefore represent a potential therapeutical agent for the treatment of hypoxic/ischemic injury and neurodegenerative diseases. Based on our studies and those of others in the literature, here we comprehensively review the role of Catalpol in neuroprotection against pathological conditions, especially in neurodegenerative states and the potential mechanisms involved.
Export Options
About this article
Cite this article as:
Jiang B., Shen R.F., Bi J., Tian X.S., Hinchliffe T and Xia Y., Catalpol: A Potential Therapeutic for Neurodegenerative Diseases, Current Medicinal Chemistry 2015; 22 (10) . https://dx.doi.org/10.2174/0929867322666150114151720
DOI https://dx.doi.org/10.2174/0929867322666150114151720 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Clinical and Computational Analysis of Variants Associated with Rare Genetic Disorders
This thematic issue focuses on integrating clinical insights and computational techniques in the study of genetic variants linked to rare genetic disorders. Rare diseases, while individually uncommon, collectively affect millions of people worldwide, making their understanding and diagnosis critical to personalized medicine. Advances in next-generation sequencing (NGS) and bioinformatics tools ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Characteristics of Bax Inhibitor-1 and its Related Diseases
Current Molecular Medicine Pomelo Peel Volatile Oil Alleviates Neuroinflammation on Focal Cerebral Ischemia Reperfusion Injury Rats via Inhibiting TLR4/NF-κB Signaling Pathway
Current Pharmaceutical Biotechnology Therapy Against Ischemic Injury
Current Pharmaceutical Design The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy
Current Medicinal Chemistry The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Matrix Metalloproteinases in Acute Coronary Syndromes: Current Perspectives
Current Topics in Medicinal Chemistry Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model
Current Drug Delivery New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Poly (ADP-Ribose) Polymerase Inhibitors as Potential Therapeutic Agents in Stroke and Neurotrauma
Current Drug Targets - CNS & Neurological Disorders Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases
Current Vascular Pharmacology Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review
Current Pharmaceutical Design